Successful progressive challenge after a cutaneous reaction to imatinib mesylate (gleevec): A case report and review of the literature

Allergy and Asthma Proceedings

Volumn 25, Issue 5, 2004, Pages 345-347

  Park, Miguel A ^a   Volcheck, Gerald W ^a   Guarderas, Juan C ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; CASE REPORT; DESENSITIZATION; DRUG ERUPTION; HUMAN; MALE; PROVOCATION TEST; REVIEW; SKIN MANIFESTATION;

ANTINEOPLASTIC AGENTS; DESENSITIZATION, IMMUNOLOGIC; DRUG ERUPTIONS; EXANTHEMA; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES;

EID: 8844246390     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001.
2. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001.
3. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared to interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003.
4. Peggs K, and Mackinnon S. Imatinib mesylate - The new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 348:1048-1050, 2003.
5. Dagher R, Cohen M, Williams G, et al. Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8: 3034-3038, 2002.
6. Demetri GD, Von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002.
7. Mace J, Biermann JS, Sondak V, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 95:2373-2379, 2002.
8. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1202-1214, 2003.
9. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90:4947-4952, 1997.
10. Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for ST-571 inhibition of abelson tyrosine kinase. Science 289:1938-1942, 2000.
11. Brouard M, and Saurat JH. Cutaneous reactions to STI571. N Engl J Med 345:618-619, 2001.
12. Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients. J Am Acad Dermatol 48:201-206, 2003.
13. Roujeau JC, and Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 331:1272-1285, 1994.
14. Konstantopoulos K, Papadogianni A, Dimopoulou M, et al. Pityriasis rosea associated with imatinib (STI 571, Gleevec). Dermatology 205:172-173, 2002.
15. Lim DS, and Muir J. Oral lichenoid reaction to imatinib (STI 571, Gleevec). Dermatology 205:169-171, 2002.
16. Hsiao LT, Chung HM, Lin JT, et al. Stevens-Johnson syndrome after treatment with STI571: A case report. Br J Haematol. 117:620-622, 2002.
17. Gruchalla RS. Drug allergy. J Allergy Clin Immunol 111: S548-S559, 2003.
18. Adkinson NF. Drug allergy. In Allergy Principles & Practice, vol 2. Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, and Busse WW (Eds.) Philadelphia: Mosby, 1212-1224, 1998.
19. Rule SA, O'Brien SG, and Crossman LC. Managing cutaneous reactions to imatinib therapy. Blood 100:3434-3435, 2002.